Special Issue "Prevention and Treatment of Bone Metastases from Breast Cancer"
A special issue of Journal of Clinical Medicine (ISSN 2077-0383).
Deadline for manuscript submissions: closed (31 July 2013)
Prof. Dr. Robert Coleman
Department of Oncology, Cancer Clinical Trials Centre, Academic Unit of Clinical Oncology, Broomcross Building, Weston Park Hospital, University of Sheffield, Sheffield, S10 2SJ, UK
Phone: +44 114 226 5213
Fax: +44 114 226 5364
Interests: cancer induced bone disease especially with relevance to breast cancer; the development of bone targeted agents in oncology, evaluation of bone markers in oncology to aid drug development and provide both prognostic and predictive information in the management of metastatic bone disease, and the assessment of adverse effects of cancer treatments on bone health and evaluation of various treatment strategies
Bone metastases are common in advanced breast cancer and cause considerable morbidity. They result from the interactions between cancer cells in the bone marrow microenvironment, haematopoietic stem cells and normal bone cells. Bone-targeted treatments may modify the course of the disease via inhibitory effects on this “vicious cycle” of growth factor and cytokine signalling between tumour and bone cells within the bone marrow micro-environment. Improvements in both disease free and overall survival in women with early breast cancer have been demonstrated with oral clodronate and in several large randomised adjuvant trials of zoledronic acid. The evidence for this is particularly strong in patients with low levels of reproductive hormones including premenopausal women receiving ovarian suppression therapy and those who have passed through menopause at the time of diagnosis. Bone-targeted agents, including bisphosphonates and denosumab, are an important component of management in advanced malignancy. Combined with systemic cancer therapy, effective symptom control and appropriate surgical and radiological interventions, modern multi-disciplinary care has transformed the care of patients with metastatic bone disease.
These reviews will cover the following important topics spanning clinical and translational cancer medicine:
- Mechanisms of metastasis
- Adjuvant therapy to prevent bone metastases
- Bone targeted treatments for the management of bone metastases
- Radiotherapy and radioisotopes for the treatment of bone metastases
- Imaging for diagnosis and monitoring of bone metastases
Prof. Dr. Robert Coleman
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- breast cancer
- bone metastases
- RANK ligand
- adjuvant therapy
- treatment induced bone loss
- vitamin D